A ginsenoside G-Rg3 PEGylated Long-Circulating liposome for hyperglycemia and insulin resistance therapy in Streptozotocin-Induced type 2 diabetes mice.

Ginsenoside (GS), one of the main active components in ginseng, can enhance insulin sensitivity, improve the function of islet ß cells, and reduce cell apoptosis in the treatment of diabetes. However, the drawbacks of high lipid solubility, poor water solubility, and low oral availability in Ginsenoside Rg3 (G-Rg3) seriously limit further application of GS. In this work, a G-Rg3 PEGylated long-circulating liposome (PEG-L-Rg3) is designed and developed to improve symptoms in type 2 diabetic mice. The as-prepared PEG-L-Rg3 with a spherical structure shows a particle size of ∼ 140.5 ±â€¯1.4 nm, the zeta potential of -0.10 ±â€¯0.05 mV, and a high encapsulation rate of 99.8 %. Notably, in vivo experimental results demonstrate that PEG-L-Rg3 exhibits efficient ability to improve body weight and food intake in streptozotocin-induced type 2 diabetic mice. Moreover, PEG-L-Rg3 also enhances fasting insulin (FINS) and insulin sensitivity index (ISI). In addition, the glucose tolerance of mice is significantly improved after the treatment of PEG-L-Rg3, indicating that PEG-L-Rg3 can be a potential drug for the treatment of type 2 diabetes, which provides a new way for the treatment of type 2 diabetes using ginsenosides.

Oral liposomes encapsulating ginsenoside compound K for rheumatoid arthritis therapy.

Ginsenoside compound K (GCK) can efficiently treat rheumatoid arthritis (RA) due to its immune and anti-inflammatory functions. However, GCK exists some shortcomings such as poor aqueous solubility, low permeability to the intestinal cell membrane, and serious P-gp efflux, thus limiting its application. In order to solve these problems, a folic acid-targeted drug delivery system based on liposomes (FA-LP-GCK) was developed. The prepared FA-LP-GCK had a uniform size distribution and spherical structure, the particle size was 249.13 ± 1.40 nm. Meanwhile, they had high encapsulation efficiency (93.33 ± 0.05 %). FA-LP-GCK also presented good stability in artificial gastric juice, so they can be absorbed into the intestine and enter the blood circulation. The activated RAW 264.7 cells were chosen to evaluate the cytotoxicity and cellular uptake capacity of FA-LP-GCK. FA-LP-GCK showed stronger growth inhibition and cellular uptake ability against activated macrophages. Finally, the efficacy of FA-LP-GCK in vivo was evaluated in the adjuvant arthritis rat model. The results showed that FA-LP-GCK can significantly reduce joint swelling. Furthermore, it can significantly inhibit the expression of pro-inflammatory cytokines and improve synovial hyperplasia of joints and pathological changes in the spleen. Therefore, FA-LP-GCK may be a potential therapeutic approach for RA.

Exosomes in cancer immunoediting and immunotherapy.

As an important means of communication among cells, exosomes are being studied more and more widely, especially in the context of cancer immunotherapy. In the phase of tumor immunoediting, exosomes derived from tumor cells and different immune cells have complex and changeable physiological functions, because they carry different proteins and nucleic acid from the source cells. Based on the role of exosomes in the communication between different cells, cancer treatment methods are also under continuous research. This review briefly introduces the molecular composition of exosomes, which is closely related to their secretion mechanism. Subsequently, the role of exosomes encapsulating different information molecules is summarized. The role of exosomes in the three phases of tumor immunoediting is introduced in detail, and the relevant literature of exosomes in the tumor immune microenvironment is summarized by using a novel framework for extracting relevant documents. Finally, it summarizes the various exosome-based immunotherapies currently proposed, as well as the challenges and future prospects of exosomes in tumor immunotherapy.

Strong multi-functions based on conjugating chondroitin sulfate onto an amine-rich surface will direct the vascular cell fate for cardiovascular implanted devices.

Thrombus, hyperplasia, and inflammation are constant threats and challenges for long-term application of cardiovascular implants. Surface endothelialization has been considered as the preferable strategy to solve these problems because of the physiological functions gained from the regenerated endothelial layers covering the implants. Thus, a surface with strong multi-functions including anti-coagulation, anti-hyperplasia, anti-inflammation, and pro-endothelialization is ideal for cardiovascular implants. Herein, we developed a novel coating by conjugating chondroitin sulfate (CS) onto an amine-rich copolymerized film of polydopamine (PDA) and hexamethylenediamine (HD), with the aim of directing the vascular cell fate. The PDA/HD-CS coating exhibited a remarkable suppression of platelet activation/aggregation and thrombosis under a blood flow of 15 dyn cm-2. Inhibition upon proliferation of vascular smooth muscle cells and attachment of macrophages were also observed on this coating. In addition, the PDA/HD-CS coating was compatible with the vascular endothelial cells, suggesting a strong pro-endothelialized function. Further in vivo tests indicated that contractile smooth muscle cells and M2 macrophages regulated by PDA/HD-CS may be involved in the regeneration of the endothelial layer. In summary, this research may support potential applications for surface modification of cardiovascular implants to achieve improved multi-functions.